Tumor-specific accumulation of 125I-labeled mouse-human chimeric anti-CEA antibody in a xenografted human cancer model demonstrated by whole-body autoradiography and immunostaining

• Published in: Nuclear medicine and biology 1996-08, Vol.23 (6), p.821-826
• Main Authors: Haruno, Masatora, Kuroki, Masahide, Matsunaga, Kazuhisa, Takata, Jiro, Karube, Yoshiharu, Senba, Tarumi, Murakami, Masaaki, Arakawa, Fumiko, Kuwahara, Motohisa, Ozaki, Hiroaki, Matsuoka, Yuji, Okazaki, Masatoshi, Kanda, Hidetoshi
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacokinetics; Autoradiography; Biological and medical sciences; Carcinoembryonic Antigen - immunology; CEA; Chimeric antibody; Contrast media. Radiopharmaceuticals; H & E staining; Histocytochemistry; Humans; Immunohistochemistry; Immunostaining; Iodine Radioisotopes; Male; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Nude; Pharmacology. Drug treatments; Radionuclide Imaging; Recombinant Fusion Proteins - immunology; Recombinant Fusion Proteins - pharmacokinetics; Stomach Neoplasms - diagnostic imaging; Stomach Neoplasms - metabolism; Stomach Neoplasms - pathology; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured; Whole-body autoradiography; Whole-Body Counting
• ISSN: 0969-8051; 1872-9614
• DOI: 10.1016/0969-8051(96)00081-9

Whole-body autoradiography (WBAR) was used to study the biodistribution of 125I-labeled mouse-human chimeric antibody (Ch F11-39) to carcinoembryonic antigen (CEA) in athymic nude mice bearing the CEA-producing MKN-45 human gastric carcinoma xenografts. Significantly high uptake of 125I-Ch F11–39 in the tumors obtained by tissue-counting technique was confirmed by WBAR of mice of 12, 24, 48, and 96 h postinjection of 125I-Ch F11–39. When compared with histochemical or immunohistochemical staining results of the tumor tissue sections, imaging profiles of 125I-Ch F11–39 obtained by WBARs were topographically correlated with histopathological findings of tissues and immunohistochemical localization of CEA in the tumor tissues, indicating that the accumulation of 125I-Ch F11–39 at the tumor site is based on its specificity for CEA. These results demonstrate that this chimeric antibody may serve as a potential useful diagnostic and/or therapeutic reagent for human CEA-producing cancers.